Carcinoma of Unknown Primary — Research

Carcinoma of Unknown Primary — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	2,027	`("Carcinoma of Unknown Primary"[tiab] OR "Cancer of Unknown Primary"[tiab] OR "Carcinoma of Unknown Primary Origin"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	791	`("Carcinoma of Unknown Primary"[tiab] OR "Cancer of Unknown Primary"[tiab] OR "Carcinoma of Unknown Primary Origin"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	154	`("Carcinoma of Unknown Primary"[tiab] OR "Cancer of Unknown Primary"[tiab] OR "Carcinoma of Unknown Primary Origin"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 51–75 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
· J Clin Oncol · 2009 · PMID 19289619 · validated civic_curation pubmed
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
· Lancet Oncol · 2014 · PMID 24793816 · validated civic_curation pubmed
Trastuzumab emtansine for HER2-positive advanced breast cancer.
· N Engl J Med · 2012 · PMID 23020162 · validated civic_curation pubmed
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.